C-POF9Telos Biotech
telomere lengthening, recombinant protein, cell therapy manufacturing
repairingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-POF9
C-POF9C-POF9telomere lengthening, recombinant protein, cell therapy manufacturing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Telos Biotech presents two core beliefs: first, that a major barrier in cell therapy is rapid telomere shortening during ex-vivo expansion, which drives senescence and exhaustion and reduces long-term therapeutic benefit; and second, that declining AMPK signaling with age contributes to dysfunctional metabolism and chronic age-related disease, so restoring AMPK activation in a monitored and controlled way can improve cellular metabolism and activate maintenance and renewal processes.
SourceTelos Biotech states that major barriers to effective cell therapy are senescence and exhaustion driven by rapid telomere shortening during cell therapy manufacturing, and it presents its work as focused on maintaining telomeres so these therapies can better realize their therapeutic potential across diseases.
SourceThe July 18, 2013 snapshot shows a GoDaddy parked-domain landing page for telosbio.com rather than company-authored website content, so it does not state any beliefs, mission, or longevity-related position attributable to the company.
SourceThis snapshot does not display any company-authored beliefs, mission, or scientific stance from TelosBio. The visible page is a GoDaddy parked-domain/for-sale page with hosting and registration marketing copy, so no reliable company position can be extracted from it.
SourceNo company-stated beliefs, mission, or longevity theory are visible in the provided Wayback snapshot text; the visible content is limited to Internet Archive capture metadata rather than Telos Bio page copy.
SourceTelos Biotech states that one of the main barriers to effective cell therapy is rapid telomere shortening during ex-vivo cell expansion, which can drive senescence or exhaustion, reduce cell lifespan, and limit durable patient benefit. The company presents Telovance as a way to rapidly and safely lengthen the shortest telomeres during manufacturing so engineered cells remain more therapeutically robust. It also states that AMPK is a critical regulator of cellular metabolism, that AMPK signaling declines with age, and that restoring AMPK activation through key signaling pathways may improve metabolism and support cell maintenance and renewal in a controlled way.
Source